CAMBRIDGE, Mass., Nov. 16, 2021 /Business Wire/ — Vesigen Therapeutics, Inc., a biotechnology company pioneering a novel extracellular vesicle non-viral delivery technology to develop transformative therapeutics, will be featured at the 3rd Exosome-Based Therapeutic Development Summit occurring November 16-18, 2021, in a presentation led by Vesigen’s Chief Scientific Officer, Joseph Nabhan, PhD.
Showcasing the reunion of leading pharma, biotech, technology providers and academic teams to advance therapeutically relevant exosome-based therapeutics in regenerative medicine, autoimmunity, COVID-19 and beyond, the 3rd Exosome-Based Therapeutic Development Summit is an exciting opportunity that marks Vesigen’s first presentation event at an industry-dedicated meeting.
The presentation highlights new data announced earlier this year on ARMMs payloading, purification and characterization, including demonstration of cellular uptake and intracellular cargo activity. These results illustrate the ability of Vesigen’s proprietary platform to produce ARMMs in a scalable process and effectively deliver functional payloads.
“Using ARMMs as drug delivery vehicles overcomes hurdles faced by other viral and non-viral delivery platforms,” said Joseph Nabhan, PhD, Chief Scientific Officer at Vesigen Therapeutics. “Vesigen has achieved unparalleled levels of intraluminal payloading into ARMMs which, along with functional intracellular delivery of cargo and extensive biodistribution studies, is permitting identification of appropriate therapeutic applications for our platform.”
About Vesigen Therapeutics
Vesigen Therapeutics is a biotechnology company advancing groundbreaking therapies directed to intracellular targets using a fusogenic extracellular vesicle delivery technology. Our patented technology, called ARMMs (ARRDC1 Mediated Microvesicles), is expanding the universe of druggable targets by enabling the delivery of a wide range of payloads, including RNAs (mRNA, shRNA, ribozymes), proteins (signaling proteins, enzymes, antibody fragments), and gene-editing complexes (Cas9/gRNA) directly into the cytoplasm of target cells. The team is committed to leveraging ARMMs technology to develop transformative medicines and address currently unmet medical needs. For additional information visit www.vesigentx.com.
ARMMs vesicles (ARRDC1-mediated microvesicles) are a class of fusogenic extracellular vesicles produced by cells to package and deliver communication signals between cells and tissues. The ARMMs cellular machinery is partially hijacked by many enveloped viruses, such as HIV and Ebola, to produce viruses which bud out of host cells and have specific targeting properties. ARMMs possess unique properties not found in other classes of extracellular vesicles (e.g. exosomes), making them better suited for delivering therapeutic agents. It has been demonstrated that a wide range of labile and difficult to deliver therapeutic agents, including RNAs (mRNA, shRNA, ribozymes), proteins (signaling proteins, enzymes, antibody fragments), and gene-editing complexes (Cas9/gRNA) can be packaged into ARMMs and functionally delivered intracellularly in vitro and in vivo. ARMMS vesicles were discovered and engineered into a drug delivery system in the lab of Quan Lu, PhD, Professor of Environmental Genetics and Physiology at the Harvard T.H. Chan School of Public Health with support in particular from Harvard’s Blavatnik Biomedical Accelerator. Vesigen will advance the ARMMs platform to develop innovative medicines for patients through an exclusive license agreement with Harvard University.
Manager, Business Operations